Knights of Columbus Asset Advisors LLC Takes Position in IDEAYA Biosciences, Inc. $IDYA

Knights of Columbus Asset Advisors LLC acquired a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the third quarter, HoldingsChannel reports. The firm acquired 34,337 shares of the company’s stock, valued at approximately $934,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Elevation Point Wealth Partners LLC bought a new position in IDEAYA Biosciences during the 2nd quarter worth about $61,000. Daiwa Securities Group Inc. lifted its holdings in shares of IDEAYA Biosciences by 16.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after purchasing an additional 436 shares in the last quarter. CWM LLC boosted its position in shares of IDEAYA Biosciences by 33.0% during the second quarter. CWM LLC now owns 3,153 shares of the company’s stock worth $66,000 after buying an additional 782 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of IDEAYA Biosciences by 39.1% during the second quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company’s stock worth $70,000 after buying an additional 940 shares in the last quarter. Finally, Signaturefd LLC lifted its stake in IDEAYA Biosciences by 58.1% in the 2nd quarter. Signaturefd LLC now owns 4,549 shares of the company’s stock valued at $96,000 after acquiring an additional 1,672 shares in the last quarter. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Down 2.4%

NASDAQ:IDYA opened at $32.19 on Friday. The firm has a market capitalization of $2.82 billion, a price-to-earnings ratio of -17.31 and a beta of 0.05. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $39.28. The stock’s 50 day moving average price is $35.00 and its two-hundred day moving average price is $29.67.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.33 earnings per share for the quarter, beating the consensus estimate of ($0.12) by $1.45. The company had revenue of $207.83 million during the quarter, compared to the consensus estimate of $59.98 million. Equities research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on IDYA. The Goldman Sachs Group lifted their price objective on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, October 21st. BTIG Research reiterated a “buy” rating and issued a $62.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. New Street Research set a $30.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 21st. Wall Street Zen upgraded IDEAYA Biosciences from a “hold” rating to a “buy” rating in a report on Sunday, November 9th. Finally, Truist Financial upped their target price on IDEAYA Biosciences from $59.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Fifteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $46.60.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.